ArticleGland surgery2026
Development and validation of a predictive nomogram for cervical lymph node metastasis in aspect ratio ≥1 papillary thyroid carcinoma using ultrasonic features and serum calcitonin.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preoperative prediction of cervical lymph node metastasis (CLNM) remains challenging in patients with papillary thyroid carcinoma (PTC) exhibiting an aspect ratio ≥1, a subgroup in which ultrasound alone has limited sensitivity (approximately 50%) and no dedicated predictive model currently exists. This study aimed to develop and internally validate a predictive nomogram combining ultrasonic features and serum calcitonin for CLNM in this specific population. Methods: This retrospective study consecutively enrolled 156 patients with aspect ratio ≥1 PTC who underwent thyroidectomy and neck lymph node dissection at a single center (November 2023 to June 2025). The gold standard outcome was pathologically confirmed CLNM. Forty-six candidate predictors (clinical, ultrasonographic, and serological variables) were collected. Predictor selection was performed using least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation, followed by multivariate logistic regression. A nomogram was constructed and internally validated using 1,000 bootstrap resamples. Model performance was assessed by area under the curve (AUC), calibration curve, sensitivity, specificity, and decision curve analysis (DCA). Results: Among 156 patients [116 females, 40 males; median age 52 years, interquartile range (IQR), 45-57 years], CLNM was present in 48 patients (30.8%). Five independent predictors were identified: multifocality [odds ratio (OR) =5.87; 95% confidence interval (CI): 1.85-18.66], maximum diameter ≥1 cm (OR =11.57; 95% CI: 2.26-59.16), ill-defined margin (OR =7.43; 95% CI: 2.06-26.76), microcalcifications (OR =3.43; 95% CI: 1.19-9.93), and serum calcitonin (OR =1.44; 95% CI: 1.08-1.92 per pg/mL). The nomogram achieved an apparent AUC of 0.834 (95% CI: 0.767-0.901) and a bootstrap-corrected AUC of 0.813. At the optimal probability cutoff of 0.264, sensitivity was 81.2% and specificity 75.9%. Calibration showed good agreement (Hosmer-Lemeshow P=0.41), and DCA demonstrated net clinical benefit across a threshold probability range of 5-80%. Conclusions: This nomogram combining five preoperative predictors shows satisfactory discriminative ability for CLNM in patients with aspect ratio ≥1 PTC. However, given the single-center design, modest sample size, and lack of external validation, these findings should be considered preliminary. External validation in independent multicenter cohorts is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.